Clayton E. Parker

Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, in its US$12 million PIPE investment in Gelteq Limited (NASDAQ: GELS). Gelteq Limited is a Victoria, Australia-headquartered clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products.

Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, regarding a US$40 million PIPE investment in Boston, Massachusetts-headquartered X4 Pharmaceuticals, Inc. (NASDAQ: XFOR), a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system.

Represented Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company, in its underwritten public offering of 1.7 million shares of its common stock at a public offering price of US$3.00 per share as a take-down off of its existing Form S-3 shelf registration statement, resulting in gross proceeds of approximately US$35 million.

Advised Anavex Life Sciences Corp. (NASDAQ: AVXL) in a US$150 million at-the-market public offering of common stock with TD Securities (USA) LLC acting as placement agent. New York, New York-based Anavex is a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease; Parkinson's disease; schizophrenia; neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome; and other central nervous system disorders.

Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, regarding a US$12 million PIPE investment in Delaware-headquartered Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a late-stage biopharmaceutical company.

Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, regarding a US$15 million PIPE investment in Delaware-headquartered SeaStar Medical Holding Corporation (NASDAQ: ICU), a commercial-stage healthcare company.

Advised Ruanyun Edai Technology Inc. (NASDAQ: RYET), a leading AI-powered education technology company in China, in its initial public offering of 3.75 million ordinary shares at a public offering price of US$4.00 per share, for aggregate gross proceeds of approximately US$15 million.

Represented CDT Environmental Technology Investment Holdings Limited (NASDAQ: CDTG), a Shenzhen, China-based waste treatment company, in its initial public offering and listing on The Nasdaq Stock Market. The offering was conducted on a firm commitment basis.

Represented Kingswood Capital Partners, LLC as the lead book-runner in the initial public offering of SolarMax Technology, Inc. (NASDAQ: SMXT), a Riverside, California-based integrated solar and renewable energy company that engages in the solar business. Kingswood Capital Partners, LLC is one of the leading wealth management and investment banking firms headquartered in New York City, New York.

Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, regarding a US$50 million PIPE investment in Cincinnati, Ohio-headquartered Workhorse Group Inc. (NASDAQ: WKHS).

Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, regarding a US$30 million PIPE investment in Toronto, Canada-headquartered Cybin Inc. (NYSE: CYBN), (NEO: CYBN).

Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, regarding a US$100 million PIPE investment in Miami, Florida-headquartered Veru Inc. (NASDAQ: VERU).

Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, regarding a US$15 million PIPE investment in Texas-based Heart Test Laboratories, Inc. (NASDAQ: HSCS).

Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, regarding a US$50 million PIPE investment in Connecticut-headquartered Chicken Soup for the Soul Entertainment, Inc. (NASDAQ: CSSE).

Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, on a US$10 million PIPE investment in Connecticut-based Aspira Women's Health Inc. (NASDAQ: AWH).

Represented QualTek USA, LLC in its acquisition of Broken Arrow Communications, Inc. ("BACOM"). QualTek USA, LLC provides communication infrastructure construction services.

Represented Enochian Biosciences, a Los Angeles-based biopharmaceutical company focused in identifying, developing, manufacturing, and commercializing gene-modified cell therapy, in its Registered Direct Offering of US$29 million of common stock.

Represented a public provider of genomic cancer testing services and its subsidiaries in connection with the refinancing of its revolving and term debt with a syndicate of financial institutions. 

Represented Anavex Life Sciences, a New York-based biopharmaceutical company engaged in developing therapies to treat Alzheimer's, Parkinson's, and other central nervous system diseases, in its registered direct offering of US$50 million of common stock.